Cargando…
Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis
Myasthenia gravis (MG) is a neuromuscular disorder leading to fluctuating muscle weakness and fatigue. Rarely, long-term stabilization is not possible through the use of thymectomy or any known drug therapy. We present our experience with extracorporeal immunoglobulin (Ig) elimination by immunoadsor...
Autores principales: | Blaha, M., Pit'ha, J., Blaha, V., Lanska, M., Maly, J., Filip, S., Langrova, H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840412/ https://www.ncbi.nlm.nih.gov/pubmed/20300435 http://dx.doi.org/10.1155/2010/419520 |
Ejemplares similares
-
Use of Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry to Demonstrate Decreased Serum Statin Levels after Extracorporeal LDL-Cholesterol Elimination
por: Bláha, M., et al.
Publicado: (2011) -
Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration
por: Studnička, Jan, et al.
Publicado: (2013) -
Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis
por: Rencová, Eva, et al.
Publicado: (2015) -
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017) -
Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)